• CSR Summary
• NCT00216476
• Primary Citation
• Data Specification

Approved Data Requests Associated with this Trial

• 2025-0352 : ALL-EMBRACED: clinicAL triaLs web-sErvice to Modify eligiBility cRiteria and pre-screening viA artifiCial intElligence methoDs
• 2024-0556 : Heterogeneity of treatment effects during guaranteed antipsychotic maintenance treatment in schizophrenia as a window into the mechanisms of treatment
• 2024-0008 : Sex differences in antipsychotic efficacy and side-effects in adults with acute exacerbations of schizophrenia: an individual-participant network meta-analysis
• 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment: An individual participant data meta-analysis
• 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
• 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
• 2021-4620 : The effects of antipsychotic discontinuation and reinstatement
• 2021-4575 : A Novel Method to Summarize Safety in Clinical Trials Using Pharmacological Class-Related Risks in FAERS
• 2020-4517 : Metabolic side effects of antipsychotic drugs during medium- to long-term treatment in schizophrenia: Systematic review and network meta-analysis
• 2020-4390 : A novel statistical approach to detect the efficacy of drugs that have heterogeneous treatment effects
• 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
• 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
• 2017-1966 : Psychosis break through antipsychotic maintenance medication: An individual participant data meta-analysis
• 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
• 2016-1005 : Identification of multivariate, clinical patterns predicting treatment response to paliperidone in schizophrenia
• 2016-0766 : Gastrointestinal disease impact on antipsychotic induced weight gain and metabolic syndrome in schizophrenia: analysis of randomized controlled trials